Aditxt Subsidiary Pearsanta Begins Clinical Study for Blood-Based Endometriosis Test

Aditxt Inc. (NASDAQ: ADTX) announced that its subsidiary Pearsanta Inc. has initiated enrollment in a prospective clinical study evaluating the Mitomic Endometriosis Test (MET), a novel blood-based diagnostic for early detection of endometriosis. The study will compare MET's performance to laparoscopic diagnosis, the current gold standard, across up to 1,000 participants referred for surgery. The first site, Dedicated to Women OB/GYN in Dover, Delaware, has begun enrollment according to the company's announcement available at https://ibn.fm/WiIhM.

Pearsanta President Chris Mitton stated that this milestone supports validation of a non-invasive diagnostic alternative that could enable earlier and more accurate detection of endometriosis. This development is significant because endometriosis currently requires invasive laparoscopic surgery for definitive diagnosis, often leading to delayed diagnosis and treatment. The condition affects approximately 10% of women of reproductive age worldwide, with many suffering for years before receiving proper diagnosis.

The blood-based test represents a potential breakthrough in women's healthcare by offering a less invasive diagnostic option that could be performed in routine clinical settings. Earlier detection through such non-invasive methods could lead to more timely interventions and improved management of symptoms for millions of women affected by this condition. The clinical study's results will be crucial in determining the test's accuracy and reliability compared to the current surgical standard.

Aditxt's approach through its subsidiary Pearsanta demonstrates the company's focus on advancing health innovations in women's health, one of four program areas the company currently operates. The successful development and validation of this test could have substantial implications for both patient care and the diagnostic testing market. Additional information about Aditxt's developments can be found in the company's newsroom at https://ibn.fm/ADTX.